A detailed history of Lord, Abbett & Co. LLC transactions in Natera, Inc. stock. As of the latest transaction made, Lord, Abbett & Co. LLC holds 1,509,231 shares of NTRA stock, worth $245 Million. This represents 0.61% of its overall portfolio holdings.

Number of Shares
1,509,231
Previous 1,509,231 -0.0%
Holding current value
$245 Million
Previous $192 Million -0.0%
% of portfolio
0.61%
Previous 0.62%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$97.75 - $129.67 $45.4 Million - $60.2 Million
-464,491 Reduced 23.53%
1,509,231 $192 Million
Q2 2024

Oct 07, 2024

BUY
$85.28 - $112.6 $15.1 Million - $20 Million
177,412 Added 9.88%
1,973,722 $214 Million
Q2 2024

Aug 14, 2024

BUY
$85.28 - $112.6 $15.1 Million - $20 Million
177,412 Added 9.88%
1,973,722 $214 Million
Q1 2024

Oct 07, 2024

BUY
$59.21 - $92.9 $59 Million - $92.6 Million
996,821 Added 124.68%
1,796,310 $164 Million
Q1 2024

May 09, 2024

BUY
$59.21 - $92.9 $59 Million - $92.6 Million
996,821 Added 124.68%
1,796,310 $164 Million
Q4 2023

Oct 07, 2024

BUY
$37.55 - $62.64 $6.81 Million - $11.4 Million
181,362 Added 29.34%
799,489 $50.1 Million
Q4 2023

Feb 12, 2024

BUY
$37.55 - $62.64 $6.81 Million - $11.4 Million
181,362 Added 29.34%
799,489 $50.1 Million
Q3 2023

Oct 07, 2024

SELL
$43.4 - $62.52 $5.89 Million - $8.49 Million
-135,759 Reduced 18.01%
618,127 $27.4 Million
Q3 2023

Nov 13, 2023

SELL
$43.4 - $62.52 $5.89 Million - $8.49 Million
-135,759 Reduced 18.01%
618,127 $27.4 Million
Q2 2023

Oct 07, 2024

SELL
$47.08 - $55.16 $5.57 Million - $6.53 Million
-118,359 Reduced 13.57%
753,886 $36.7 Million
Q2 2023

Aug 14, 2023

SELL
$47.08 - $55.16 $5.57 Million - $6.53 Million
-118,359 Reduced 13.57%
753,886 $36.7 Million
Q1 2023

Oct 07, 2024

BUY
$36.57 - $58.29 $10.9 Million - $17.4 Million
298,420 Added 52.01%
872,245 $48.4 Million
Q1 2023

May 12, 2023

BUY
$36.57 - $58.29 $10.9 Million - $17.4 Million
298,420 Added 52.01%
872,245 $48.4 Million
Q4 2022

Oct 07, 2024

SELL
$34.17 - $47.91 $47.8 Million - $67.1 Million
-1,399,897 Reduced 70.93%
573,825 $23.1 Million
Q4 2022

Feb 10, 2023

BUY
$34.17 - $47.91 $8.05 Million - $11.3 Million
235,561 Added 69.64%
573,825 $23.1 Million
Q3 2022

Nov 14, 2022

BUY
$36.93 - $56.68 $12.5 Million - $19.2 Million
338,264 New
338,264 $14.8 Million
Q2 2022

Aug 12, 2022

SELL
$28.13 - $44.54 $3.15 Million - $4.99 Million
-112,138 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$30.32 - $91.33 $14.1 Million - $42.6 Million
-466,587 Reduced 80.62%
112,138 $4.56 Million
Q4 2021

Feb 11, 2022

SELL
$86.26 - $119.0 $32.8 Million - $45.3 Million
-380,552 Reduced 39.67%
578,725 $54 Million
Q3 2021

Nov 09, 2021

SELL
$100.17 - $126.36 $3.88 Million - $4.9 Million
-38,779 Reduced 3.89%
959,277 $107 Million
Q2 2021

Aug 11, 2021

SELL
$86.05 - $119.72 $40.5 Million - $56.3 Million
-470,141 Reduced 32.02%
998,056 $113 Million
Q1 2021

May 11, 2021

BUY
$91.47 - $124.36 $44.6 Million - $60.6 Million
487,579 Added 49.72%
1,468,197 $149 Million
Q4 2020

Feb 09, 2021

SELL
$66.66 - $111.74 $401,693 - $673,345
-6,026 Reduced 0.61%
980,618 $97.6 Million
Q3 2020

Nov 12, 2020

BUY
$45.89 - $72.67 $7.33 Million - $11.6 Million
159,804 Added 19.33%
986,644 $71.3 Million
Q2 2020

Aug 14, 2020

BUY
$26.36 - $49.86 $7.46 Million - $14.1 Million
282,976 Added 52.03%
826,840 $41.2 Million
Q1 2020

May 14, 2020

BUY
$17.27 - $40.17 $705,479 - $1.64 Million
40,850 Added 8.12%
543,864 $16.2 Million
Q4 2019

Feb 14, 2020

BUY
$32.1 - $40.4 $11.3 Million - $14.2 Million
350,488 Added 229.79%
503,014 $16.9 Million
Q3 2019

Nov 14, 2019

BUY
$25.38 - $34.89 $3.87 Million - $5.32 Million
152,526 New
152,526 $5 Million

Others Institutions Holding NTRA

About Natera, Inc.


  • Ticker NTRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 96,957,400
  • Market Cap $15.7B
  • Description
  • Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify sing...
More about NTRA
Track This Portfolio

Track Lord, Abbett & Co. LLC Portfolio

Follow Lord, Abbett & Co. LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lord, Abbett & Co. LLC with notifications on news.